DE69127175T2 - Antisens-Oligonukleotide zur Behandlung von Krebs - Google Patents
Antisens-Oligonukleotide zur Behandlung von KrebsInfo
- Publication number
- DE69127175T2 DE69127175T2 DE69127175T DE69127175T DE69127175T2 DE 69127175 T2 DE69127175 T2 DE 69127175T2 DE 69127175 T DE69127175 T DE 69127175T DE 69127175 T DE69127175 T DE 69127175T DE 69127175 T2 DE69127175 T2 DE 69127175T2
- Authority
- DE
- Germany
- Prior art keywords
- antisense oligonucleotides
- cancer
- treatment
- animals
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60711390A | 1990-11-02 | 1990-11-02 | |
US68019891A | 1991-04-05 | 1991-04-05 | |
US07/702,163 US5271941A (en) | 1990-11-02 | 1991-05-20 | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69127175D1 DE69127175D1 (de) | 1997-09-11 |
DE69127175T2 true DE69127175T2 (de) | 1998-03-12 |
Family
ID=27416969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69132299T Expired - Fee Related DE69132299T2 (de) | 1990-11-02 | 1991-10-31 | Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von Krebs |
DE69127175T Expired - Fee Related DE69127175T2 (de) | 1990-11-02 | 1991-10-31 | Antisens-Oligonukleotide zur Behandlung von Krebs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69132299T Expired - Fee Related DE69132299T2 (de) | 1990-11-02 | 1991-10-31 | Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von Krebs |
Country Status (9)
Country | Link |
---|---|
US (3) | US5271941A (de) |
EP (3) | EP0785252B1 (de) |
KR (1) | KR0171210B1 (de) |
AT (2) | ATE194383T1 (de) |
CA (2) | CA2488792A1 (de) |
DE (2) | DE69132299T2 (de) |
DK (2) | DK0490077T3 (de) |
ES (2) | ES2104644T3 (de) |
GR (2) | GR3024673T3 (de) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US5359052A (en) * | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US5646267A (en) * | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US6995146B2 (en) * | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
EP0750516A4 (de) | 1993-03-26 | 1998-07-01 | Univ Jefferson | Verfahren zur hemmung der zellvermehrung und zur zelldifferenzierung mit antisense oligonukleotiden für den igf-1 rezeptor |
US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
ES2326118T3 (es) * | 1993-09-20 | 2009-10-01 | The Trustees Of The University Of Pennsylvania | Regulacion de la expresion del gen bcl-2. |
US5618709A (en) * | 1994-01-14 | 1997-04-08 | University Of Pennsylvania | Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein |
US5726297A (en) * | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
US5599922A (en) * | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US6608035B1 (en) | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
US6624293B1 (en) * | 1995-08-17 | 2003-09-23 | Hybridon, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US7074768B2 (en) * | 1995-08-17 | 2006-07-11 | Idera Pharmaceuticals, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US20050054600A1 (en) * | 1995-08-17 | 2005-03-10 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotides and methods of their use |
US5969117A (en) * | 1995-08-17 | 1999-10-19 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotide |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
WO1998040479A1 (en) * | 1997-03-12 | 1998-09-17 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotides and methods of their use |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US6312941B1 (en) | 1997-11-26 | 2001-11-06 | The Regents Of The University Of Michigan | Compositions and methods for identifying signaling pathway agonists and antagonists |
AU5618700A (en) * | 1999-06-18 | 2001-01-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US6489356B2 (en) | 2000-09-05 | 2002-12-03 | Edward Leung | Method for treating pain in humans |
AU2001296305B2 (en) | 2000-09-26 | 2007-12-06 | Duke University | RNA aptamers and methods for identifying the same |
EP2336166A1 (de) | 2000-10-12 | 2011-06-22 | University Of Rochester | Zusammensetzungen die die Proliferation von Krebszellen hemmen |
KR100408916B1 (ko) * | 2000-11-23 | 2003-12-11 | 주식회사 바이오제니아 | 마이코락톤을 함유하는 항암제, 사람 레티노블라스토마단백질의 발현을 저하시키는 안티센스 올리고누클레오티드및 마이코락톤과 상기 안티센스 올리고누클레오티드를함유하는 항암제 |
US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
JP2005532263A (ja) | 2002-02-06 | 2005-10-27 | ヴァイコー テクノロジーズ, インコーポレイテッド | 抗梗塞分子 |
EP1534729A2 (de) * | 2002-02-26 | 2005-06-01 | University of Utah Research Foundation | Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten |
AU2003257181A1 (en) | 2002-08-05 | 2004-02-23 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
US7528117B2 (en) * | 2002-12-05 | 2009-05-05 | The Research Foundation Of State University Of New York | High efficacy antisense RIαPKA poly-DNP oligoribonucleotides |
WO2006031210A1 (en) * | 2003-05-29 | 2006-03-23 | Board Of Regents, The University Of Texas Systems | Jabi as a prognostic marker and a therapeutic target for human cancer |
AU2005247319B2 (en) * | 2004-04-28 | 2011-12-01 | Molecules For Health, Inc. | Methods for treating or preventing restenosis and other vascular proliferative disorders |
WO2005112978A2 (en) | 2004-05-21 | 2005-12-01 | University Of Utah Research Foundation | Methods and compositions related to delivery of chemical compounds to invertebrate embryos |
EP2484780A1 (de) | 2004-07-23 | 2012-08-08 | The University of North Carolina At Chapel Hill | Verfahren und Materialien zur Bestimmung der Schmerzempfindlichkeit und Vorhersage und Behandlung zugehöriger Störungen |
SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
US8703769B2 (en) * | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP2189522A1 (de) | 2005-10-14 | 2010-05-26 | MUSC Foundation For Research Development | PAX2 als Ziel zur Induktion einer Immunität gegen DEFB1-vermittelte Tumore und bei der Krebstherapie |
SI2056845T1 (en) | 2006-08-08 | 2018-02-28 | Rheinische Friedrich-Wilhelms-Universitaet Bonn | STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES |
JP5926475B2 (ja) | 2006-09-21 | 2016-05-25 | ユニバーシティー オブ ロチェスター | 筋緊張性ジストロフィーのためのタンパク質置換治療に関する組成物および方法 |
WO2008136852A2 (en) | 2006-11-01 | 2008-11-13 | University Of Rochester | Methods and compositions related to the structure and function of apobec3g |
JP2010512327A (ja) | 2006-12-11 | 2010-04-22 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 病的血管形成および脈管透過性の処置用の組成物および方法 |
US9526707B2 (en) * | 2007-08-13 | 2016-12-27 | Howard L. Elford | Methods for treating or preventing neuroinflammation or autoimmune diseases |
WO2009032693A2 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
US7828840B2 (en) * | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
EP2268664B1 (de) | 2007-12-03 | 2017-05-24 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Doc1-zusammensetzungen und verfahren zur behandlung von krebs |
WO2009137686A1 (en) | 2008-05-08 | 2009-11-12 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
WO2010027641A2 (en) * | 2008-08-15 | 2010-03-11 | Georgetown University | Na channels, disease, and related assays and compositions |
WO2010065617A1 (en) | 2008-12-02 | 2010-06-10 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
WO2011031974A1 (en) | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
WO2014093688A1 (en) | 2012-12-12 | 2014-06-19 | 1Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
EP3071590A4 (de) | 2013-11-21 | 2017-07-19 | SeNA Research, Inc. | Verfahren zur strukturbestimmung von selenderivatisierten nukleinsäurekomplexen |
AU2015298263B2 (en) | 2014-07-31 | 2020-05-14 | Anji Pharmaceuticals, Inc. | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
ES2893114T3 (es) | 2015-02-04 | 2022-02-08 | Bristol Myers Squibb Co | Métodos para seleccionar moléculas terapéuticas |
RU2017127609A (ru) * | 2015-02-04 | 2019-03-04 | Ф. Хоффманн-Ля Рош Аг | Антисмысловые олигомеры тау-белка и их применение |
CN109563516B (zh) | 2016-07-28 | 2023-10-27 | 雷杰纳荣制药公司 | Gpr156变体及其用途 |
CN110087665A (zh) | 2016-08-03 | 2019-08-02 | H·李·莫菲特癌症中心与研究所公司 | Tlr9靶向治疗 |
MX2019008675A (es) | 2017-01-23 | 2019-09-18 | Regeneron Pharma | Variantes de hidroxiesteroide 17-beta deshidrogenasa 13 (hsd17b13) y usos de estas. |
EP3635102A1 (de) | 2017-06-05 | 2020-04-15 | Regeneron Pharmaceuticals, Inc. | B4galt1-varianten und verwendungen davon |
SG11202001754RA (en) | 2017-09-06 | 2020-03-30 | Regeneron Pharma | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof |
JP2020536500A (ja) | 2017-09-07 | 2020-12-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 溶質キャリアファミリー14メンバー1(slc14a1)の変異型及びその使用 |
CA3078883A1 (en) | 2017-10-11 | 2019-04-18 | Regeneron Pharmaceuticals, Inc. | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation |
JP2021501601A (ja) | 2017-10-16 | 2021-01-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | コルヌリン(crnn)バリアント及びその使用 |
US11957687B2 (en) | 2019-07-02 | 2024-04-16 | Regeneron Pharmaceuticals, Inc. | Modulators of HSD17B13 and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
NO864301L (no) * | 1986-10-28 | 1988-04-29 | Tore Jahnsen | Dna-prober for human regulatorisk enhet av camp-avhengige proteinkinaser. |
WO1990000624A1 (en) * | 1988-07-05 | 1990-01-25 | Baylor College Of Medecine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
-
1991
- 1991-05-20 US US07/702,163 patent/US5271941A/en not_active Expired - Lifetime
- 1991-10-28 CA CA002488792A patent/CA2488792A1/en not_active Abandoned
- 1991-10-28 CA CA002054325A patent/CA2054325C/en not_active Expired - Fee Related
- 1991-10-31 EP EP97100277A patent/EP0785252B1/de not_active Expired - Lifetime
- 1991-10-31 AT AT97100277T patent/ATE194383T1/de not_active IP Right Cessation
- 1991-10-31 DK DK91118628.6T patent/DK0490077T3/da active
- 1991-10-31 ES ES91118628T patent/ES2104644T3/es not_active Expired - Lifetime
- 1991-10-31 AT AT91118628T patent/ATE156517T1/de not_active IP Right Cessation
- 1991-10-31 DK DK97100277T patent/DK0785252T3/da active
- 1991-10-31 DE DE69132299T patent/DE69132299T2/de not_active Expired - Fee Related
- 1991-10-31 ES ES97100277T patent/ES2148838T3/es not_active Expired - Lifetime
- 1991-10-31 EP EP91118628A patent/EP0490077B1/de not_active Expired - Lifetime
- 1991-10-31 EP EP99119780A patent/EP0972831A1/de not_active Withdrawn
- 1991-10-31 DE DE69127175T patent/DE69127175T2/de not_active Expired - Fee Related
- 1991-11-02 KR KR1019910019468A patent/KR0171210B1/ko not_active IP Right Cessation
-
1993
- 1993-05-14 US US08/060,984 patent/US5627158A/en not_active Expired - Fee Related
-
1995
- 1995-02-02 US US08/383,742 patent/US5691317A/en not_active Expired - Fee Related
-
1997
- 1997-09-10 GR GR970402319T patent/GR3024673T3/el unknown
-
2000
- 2000-10-02 GR GR20000402225T patent/GR3034535T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2488792A1 (en) | 1992-05-03 |
ATE156517T1 (de) | 1997-08-15 |
GR3034535T3 (en) | 2001-01-31 |
CA2054325C (en) | 2005-03-15 |
DK0490077T3 (da) | 1998-01-26 |
EP0490077A1 (de) | 1992-06-17 |
CA2054325A1 (en) | 1992-05-03 |
EP0785252A1 (de) | 1997-07-23 |
GR3024673T3 (en) | 1997-12-31 |
ATE194383T1 (de) | 2000-07-15 |
DK0785252T3 (da) | 2000-10-02 |
DE69132299T2 (de) | 2001-02-15 |
DE69127175D1 (de) | 1997-09-11 |
ES2148838T3 (es) | 2000-10-16 |
US5627158A (en) | 1997-05-06 |
EP0785252B1 (de) | 2000-07-05 |
KR0171210B1 (ko) | 1999-02-01 |
ES2104644T3 (es) | 1997-10-16 |
EP0490077B1 (de) | 1997-08-06 |
EP0972831A1 (de) | 2000-01-19 |
US5271941A (en) | 1993-12-21 |
DE69132299D1 (de) | 2000-08-10 |
US5691317A (en) | 1997-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69127175T2 (de) | Antisens-Oligonukleotide zur Behandlung von Krebs | |
DE69310634D1 (de) | Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
BR9814857A (pt) | Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril | |
DE69230046T2 (de) | 2-Bromomelatonin zur Behandlung von Schlafstörungen | |
DE69731652D1 (de) | Verfahren zur behandlung von endothelialen verletzungen | |
DE3870508D1 (de) | Zusammensetzung zur behandlung des haares. | |
DE3882775D1 (de) | Zusammensetzung zur behandlung von parodontaler krankheit. | |
BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
PT88275A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos | |
HUT51594A (en) | Process for production of celates and their complexes containing ortolizating functional groups, compositions containing such active substances and process for production of conjugates consisting of one complex and linked to it antibody or fragment of antibody | |
DE69429806T2 (de) | Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung | |
DE69233725D1 (de) | Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren | |
ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
DE69000960T2 (de) | Zusammensetzung zur behandlung von pigmentierung. | |
DE69425345D1 (de) | Anwendung von Selegilin in Tiermedizin | |
DE69111457D1 (de) | Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien. | |
DE69112718D1 (de) | Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen. | |
DE3782661T2 (de) | Pharmazeutische zusammensetzungen zur behandlung von krebs. | |
DE68914886D1 (de) | Mittel zur Behandlung von Raynaud's Krankheit. | |
DE58904510D1 (de) | Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen. | |
RU95106650A (ru) | Фармацевтические композиции для предотвращения образования метастазов рака в печени и фармацевтическая композиция для лечения рака печени, способ лечения, способ получения композиции, применение цитарабин окфосфата для получения фармацевтической композиции | |
ATE338541T1 (de) | Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |